David E. Magee

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

Larry J. Black, Masahiko Sato, Ellen R. Rowley et al. · Journal of Clinical Investigation · 1994 · 612 citations · Full text

Lipid Peroxidation, Gynecology, Pharmacotherapy +20

Structure−Activity Relationships of Selective Estrogen Receptor Modulators:  Modifications to the 2-Arylbenzothiophene Core of Raloxifene

Timothy A. Grese, Stephen Cho, Don R. Finley et al. · Journal of Medicinal Chemistry · 1997 · 175 citations · Full text

Gynecology, Raloxifene Analogs, Pharmacotherapy +23

Environmental estrogens: Effects on cholesterol lowering and bone in the ovariectomized rat

Jeffrey A. Dodge, Andrew L. Glasebrook, David E. Magee et al. · The Journal of Steroid Biochemistry and Molecular Biology · 1996 · 149 citations

Ovariectomized Rat, Physiology, Gynecology +12

Synthesis and Pharmacology of Conformationally Restricted Raloxifene Analogues:  Highly Potent Selective Estrogen Receptor Modulators

Timothy A. Grese, Lewis D. Pennington, James P. Sluka et al. · Journal of Medicinal Chemistry · 1998 · 126 citations

Dual-energy X-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats

Masahiko Sato, Cindy McClintock, John Kim et al. · Journal of Bone and Mineral Research · 1994 · 105 citations